When a stock that's relatively stable suddenly sees an 8.3% one-day spike – and on volume that's over five times higher than its regular daily average – it's time to pay attention.

That's precisely what happened to biopharmaceutical and diagnostics company Opko Health (OPK), on Monday.

It's been an okay year for the Miami-based firm, with shares up over 8% year to date.

But an 8.3% one-day spike is an anomaly. So is the sudden rise warranted?

Thanks to a recent deal with Pfizer (PFE), it might be…

Opko's Rough Year

Let's take a look at Opko's recent results…

Revenue: In the third quarter, the company reported $19.8 million in total revenue – a decline of 3.9% over Q3 2013. Not only that, the 2014 year-to-date numbers showed even worse results, with revenue slumping from $75.8 million to $65.6 million – a 13.4% drop.

Net Loss: While the company managed to narrow its quarterly net loss from $60 million a year ago to $48.7 million, it was still a wider loss than anticipated. And again, year-to-date results tell a fuller story. Net loss for the nine months was $118.7 million, versus the $98 million over the first nine months of 2013.

Profit Margin: It's another case of one step forward, two steps back, here, as well. Opko reported a strong gross profit margin of 46.7%, but its net profit margin of -246.1% is significantly below the industry average.

Cash Flow: Opko's net operating cash flow suffered a huge 83.7% decline to a loss of $21 million.

To summarize those results, it's a mixed bag… at best.

So Opko's sudden price rise seems inexplicable, right?

Well, not entirely…

Pfizer-Fueled Gains on the Horizon

On the plus side, Opko boasts very low debt and a current ratio of 2.12, which shows that the company has the ability to meet its short-term liquidity needs.

But here's a bigger reason why investors should remain bullish…